Lulizumab
Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib , Lulizumab can regulate immune cells and prolong the survival time of the graft[1][2].
Product Specifications
CAS Number
2235419-62-0
Product Name Alternative
Humanized Anti-CD28 Recombinant Antibody
UNSPSC
12352203
Target
CD28
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lulizumab.html
Purity
95.0
Solubility
H2O
Smiles
[Lulizumab]
Molecular Weight
(12.01 kDa)
References & Citations
[1]Fernandes JC. Therapeutic application of antibody fragments in autoimmune diseases: current state and prospects. Drug Discov Today. 2018 Dec;23 (12) :1996-2002.|[2]Schroder PM, et al. Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model. Kidney Int. 2021 Jan;99 (1) :161-172.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
